Deguchi K, Yokota N, Koguchi M, Nakane Y, Suzuki Y, Fukayama S, Ishihara R, Oda S
Section of Studies, Tokyo Clinical Research Center.
Jpn J Antibiot. 1992 Oct;45(10):1305-11.
Antibacterial effects of combination use of arbekacin (ABK) with cefotiam (CTM) or cefuzonam (CZON) were evaluated against methicillin-resistant Staphylococcus aureus (MRSA) and the following results were obtained. 1. Antibacterial effects of combinations of ABK with CTM and with CZON were equally potent against MRSA at clinically expected 1 MIC of ABK in blood. However, at a sub MIC of ABK the different effects were observed between the 2 combinations. The antibacterial effect of the former was strong and that of the latter was a little weak. 2. In either combination the potency of the antibacterial activity was less dependent on the concentration of CTM or CZON, but was strongly dependent on ABK concentrations. These results suggest that antibacterial effects of the combinations were highly dependent on antibacterial potency and concentration of ABK as previously reported for combinations of ABK with other drugs. 3. The combination use of ABK with CTM appears to be useful in cases of infection by MRSA alone while the combination use of ABK with CZON appears to be useful in cases of double infection with MRSA and Gram-negative bacterium.
评估了阿贝卡星（ABK）与头孢替安（CTM）或头孢唑肟（CZON）联合使用对耐甲氧西林金黄色葡萄球菌（MRSA）的抗菌效果，结果如下。1. 在临床上预期的血液中阿贝卡星1倍最低抑菌浓度（MIC）时，阿贝卡星与头孢替安及与头孢唑肟联合使用对MRSA的抗菌效果相当。然而，在阿贝卡星低于MIC时，两种联合用药之间观察到不同的效果。前者的抗菌效果强，后者稍弱。2. 在任何一种联合用药中，抗菌活性的强度较少依赖于头孢替安或头孢唑肟的浓度，而是强烈依赖于阿贝卡星的浓度。这些结果表明，联合用药的抗菌效果高度依赖于抗菌效力和阿贝卡星的浓度，正如之前报道的阿贝卡星与其他药物联合使用的情况。3. 阿贝卡星与头孢替安联合使用似乎对单纯MRSA感染病例有用，而阿贝卡星与头孢唑肟联合使用似乎对MRSA和革兰氏阴性菌双重感染病例有用。
